These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 36594136

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

  • 11. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X, Yang M, Wang L, Li L, Zhong X.
    Medicine (Baltimore); 2021 May 14; 100(19):e25795. PubMed ID: 34106616
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y, Zhao Z, Wang X, Zuo W, Zhang B, Yuan T, Fu Y.
    Immunotherapy; 2021 Apr 14; 13(6):483-489. PubMed ID: 33626915
    [Abstract] [Full Text] [Related]

  • 14. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
    Huang W, Liu Y, Li M, Xue Y, Bao W, Guo Y.
    Medicine (Baltimore); 2023 Nov 10; 102(45):e35946. PubMed ID: 37960733
    [Abstract] [Full Text] [Related]

  • 15. Type 1 diabetes related to immune checkpoint inhibitors.
    Tachibana M, Imagawa A.
    Best Pract Res Clin Endocrinol Metab; 2022 May 10; 36(3):101657. PubMed ID: 35450793
    [Abstract] [Full Text] [Related]

  • 16. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
    Harsch IA, Konturek PC.
    Wiad Lek; 2018 May 10; 71(5):945-948. PubMed ID: 30176620
    [Abstract] [Full Text] [Related]

  • 17. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
    Edahiro R, Ishijima M, Kurebe H, Nishida K, Uenami T, Kanazu M, Akazawa Y, Yano Y, Mori M.
    Thorac Cancer; 2019 May 29; 10(5):1276-1279. PubMed ID: 30964601
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.